Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Di Carlo A, Bellino L, Consoli D et al. Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project. Europace 21(10), 1468–1475 (2019).
  MedlineGoogle Scholar
• 2. Public Health England (PHE). Atrial fibrillation prevalence estimates in England: application of recent population estimates of AF in Sweden. (2017).
  Google Scholar
• 3. Lane DA, Skjoth F, Lip GYH, Larsen TB, Kotecha D. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. J. Am. Heart Assoc. 6(5), pii:e005155(2017). doi: 10.1161/JAHA.116.005155. • Analysis of the UK Clinical Practice Research Datalink from 1998 to 2010 to provide insight on incidence, prevalence and mortality of atrial fibrillation.
  Google Scholar
• 4. Rozen G, Hosseini SM, Kaadan MI et al. Emergency department visits for atrial fibrillation in the United States: trends in admission rates and economic burden from 2007 to 2014. J. Am. Heart Assoc. 7(15), e009024(2018). doi: 10.1161/JAHA.118.009024.
  MedlineGoogle Scholar
• 5. Clinical Knowledge Summaries - Atrial fibrillation. National Institute for Health and Care Excellence guideline-development group's (GDG's) expert opinion (2020) https://cks.nice.org.uk/atrial-fibrillation
  Google Scholar
• 6. Rogenstein C, Kelly A-M, Mason S et al. An international view of how recent-onset atrial fibrillation is treated in the emergency department. Acad. Emerg. Med. 19(11), 1255–1260 (2012).
  MedlineGoogle Scholar
• 7. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. J. Cardiothorac. Surg. 50(5), e1–e88 (2016). •• European Society of Cardiology guidelines including information on rate and rhythm control for the management of acute onset atrial fibrillation.
  MedlineGoogle Scholar
• 8. Summary of Product Characteristics. Amiodarone Hydrochloride 50mg/ml Concentrate for Solution for Injection/Infusion. Hameln Pharmaceuticals (2019). https://www.medicines.org.uk/emc/product/3940/smpc#companyDetails
  Google Scholar
• 9. Medical Information (2016). https://www.pfizermedicalinformation.com/en-us/corvert/warnings
  Google Scholar
• 10. European Medicines Agency Summary of product characteristics. Brinavess 20 mg/ml concentrate for solution for infusion. Correvio, UK (2015). https://www.medicines.org.uk/emc/product/7249/smpc • Manufacturer’s information on vernakalant, including information on contraindications, side effects and drug interactions.
  Google Scholar
• 11. Summary of Product Characteristics. Arythmol 150mg Tablets. Mylan (2020). https://www.medicines.org.uk/emc/product/1733/smpc#
  Google Scholar
• 12. Summary of Product Characteristics. Flecainide Acetate 50mg tablets. Aurobindo Pharma - Milpharm (2018). https://www.medicines.org.uk/emc/product/3087/smpc#companyDetails
  Google Scholar
• 13. The Food and Drug Administration. Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting. Topic: New Drug Application 22034. Vernakalant Hydrochloride Injection for the Rapid Conversion of Recent Onset Atrial Fibrillation. ]https://www.fda.gov/media/133297/download
  Google Scholar
• 14. Vernakalant Compound Summary. https://pubchem.ncbi.nlm.nih.gov/compound/Vernakalant
  Google Scholar
• 15. Mao ZL, Wheeler JJ, Clohs L, Beatch GN, Keirns J. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J. Clin. Pharmacol. 49(1), 17–29 (2009).
  Medline CASGoogle Scholar
• 16. European Medicines Agency (EMA). European Public Assessment Report — Brinvavess (2010). https://www.ema.europa.eu/en/documents/assessment-report/brinavess-epar-public-assessment-report_en.pdf
  Google Scholar
• 17. Finnin M. Vernakalant: a novel agent for the termination of atrial fibrillation. Am. J. Health Syst. Pharm. 67(14), 1157–1164 (2010).
  Medline CASGoogle Scholar
• 18. Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin. Investig. Drugs 16(4), 519–532 (2007).
  Medline CASGoogle Scholar
• 19. Wettwer E, Christ T, Endig S et al. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation. Cardiovasc. Res. 98(1), 145–154 (2013).
  Medline CASGoogle Scholar
• 20. Camm AJ. The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A.? Curr. Cardiol. Rev. 10(4), 309–314 (2014).
  MedlineGoogle Scholar
• 21. Kossaify A. Vernakalant in atrial fibrillation: a relatively new weapon in the armamentarium against an old enemy. Drug Target Insights 13, doi: 10.1177/1177392819861114 (2019) (Epub ahead of print).
  MedlineGoogle Scholar
• 22. Heidbuchel H, Vereecke J, Carmeliet E. Three different potassium channels in human atrium. Contribution to the basal potassium conductance. Circ. Res. 66(5), 1277–1286 (1990).
  Medline CASGoogle Scholar
• 23. Wettwer E, Amos G, Gath J, Zerkowski HR, Reidemeister JC, Ravens U. Transient outward current in human and rat ventricular myocytes. Cardiovasc. Res. 27(9), 1662–1669 (1993).
  Medline CASGoogle Scholar
• 24. Oudit GY, Kassiri Z, Sah R, Ramirez RJ, Zobel C, Backx PH. The molecular physiology of the cardiac transient outward potassium current (I(to)) in normal and diseased myocardium. J. Mol. Cell Cardiol. 33(5), 851–872 (2001).
  Medline CASGoogle Scholar
• 25. Beuckelmann DJ, Nabauer M, Erdmann E. Alterations of K+ currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ. Res. 73(2), 379–385 (1993).
  Medline CASGoogle Scholar
• 26. Ravens U, Wettwer E. Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications. Cardiovasc. Res. 89(4), 776–785 (2010).
  MedlineGoogle Scholar
• 27. Podd SJ, Freemantle N, Furniss SS, Sulke N. First clinical trial of specific IKACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation. Europace 18(3), 340–346 (2016).
  MedlineGoogle Scholar
• 28. Van Wagoner David R, Pond Amber L, Mccarthy Patrick M, Trimmer James S, Nerbonne Jeanne M. Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ. Res. 80(6), 772–781 (1997).
  MedlineGoogle Scholar
• 29. Camm AJ, Dorian P, Hohnloser SH et al. A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation. Eur. Heart J. Cardiovasc. Pharmacother. 5(1), 21–28 (2019).
  MedlineGoogle Scholar
• 30. Camm AJ, Toft E, Torp-Pedersen C et al. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. Europace 14(6), 804–809 (2012).
  MedlineGoogle Scholar
• 31. Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic SS, Beatch GN. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J. Cardiovasc. Pharmacol. 50(1), 35–40 (2007).
  Medline CASGoogle Scholar
• 32. Pratt CM, Roy D, Torp-Pedersen C et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am. J. Cardiol. 106(9), 1277–1283 (2010).
  Medline CASGoogle Scholar
• 33. Beatch G, Mangal B. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial. BMC Cardiovasc. Disord. 16, 113 (2016).
  MedlineGoogle Scholar
• 34. Beatch GN, Bhirangi K, Juul-Moller S, Rustige J. Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in the asia-pacific region: a Phase 3 randomized controlled trial. J. Cardiovasc. Pharmacol. 69(2), 86–92 (2017).
  Medline CASGoogle Scholar
• 35. Kowey PR, Dorian P, Mitchell LB et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ. Arrhythm. Electrophysiol. 2(6), 652–659 (2009).
  MedlineGoogle Scholar
• 36. Roy D, Rowe BH, Stiell IG et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J. Am. Coll. Cardiol. 44(12), 2355–2361 (2004).
  Medline CASGoogle Scholar
• 37. Roy D, Pratt CM, Torp-Pedersen C et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation. Circulation 117(12), 1518–1525 (2008).
  Medline CASGoogle Scholar
• 38. Simon A, Niederdoeckl J, Skyllouriotis E et al. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department. 19(2), 233-240 (2017).
  Google Scholar
• 39. Vogiatzis I, Papavasiliou E, Dapcevitch I, Pittas S, Koulouris E. Vernakalant versus ibutilide for immediate conversion of recent-onset atrial fibrillation. Hippokratia 21(2), 67–73 (2017).
  Medline CASGoogle Scholar
• 40. Camm AJ, Capucci A, Hohnloser SH et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J. Am. Coll. Cardiol. 57(3), 313–321 (2011).
  MedlineGoogle Scholar
• 41. Mcintyre WF, Healey JS, Bhatnagar AK et al. Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis. Europace 21(8), 1159–1166 (2019). •• This systematic review and meta-analysis summarizes the trial data available on the efficacy and safety of vernakalant.
  MedlineGoogle Scholar
• 42. Ma W, Guo X, Wang Q, Sun G, Wang J. Systematic review and meta-analysis appraising efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation. J. Cardiovasc. Pharmacol. (2020) (Epub ahead of print). doi:10.1097/FJC.0000000000000832 •• This systematic review and meta-analysis summarized the data available from trials and observational studies on the efficacy and safety of vernakalant.
  Google Scholar
• 43. Desouza IS, Tadrous M, Sexton T, Benabbas R, Carmelli G, Sinert R. Pharmacologic cardioversion of recent-onset atrial fibrillation and flutter in the emergency department: a systematic review and network meta-analysis. Ann. Emerg. Med. doi:https://doi.org/10.1016/j.annemergmed.2020.01.013 (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 44. Domanovits H, Carbajosa Dalamau J, Hartikainen J, Juhlin T, Ritz B, Levy S. Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in real-world clinical practice: the SPECTRUM post-approval safety study, European Society of Cardiology Congress (2019). https://doi.org/10.1093/eurheartj/ehz745.1151 •• Real-world study conducted in response to the EMA request of further safety data for vernakalant after approval in 2010, subsequently used as part of a New Drug Resubmission to the US FDA in 2019 to provide evidence of safety.
  Google Scholar
• 45. Cosin-Sales J, Loscos A, Peiro A, Sorando MR, Buendia F, Ruescas L. Real-world data on the efficacy of vernakalant for pharmacological cardioversion in patients with recent-onset atrial fibrillation. Rev. Esp. Cardiol. 69(6), 619–620 (2016).
  MedlineGoogle Scholar
• 46. Stoneman P, Gilligan P, Mahon P, Sheahan R. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge. Ir. J. Med. Sci. 186(4), 903–908 (2017).
  Medline CASGoogle Scholar
• 47. Carbajosa Dalmau J, Cosín-Sales J, Pérez-Durá MJ et al. [Vernakalant in hospital emergency practice: safety and effectiveness]. Emergencias 29(6), 397–402 (2017).
  MedlineGoogle Scholar
• 48. Pohjantähti-Maaroos H, Hyppölä H, Hartikainen J, Lekkala M, Sinisalo E, Heikkola A. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation. Eur. Heart J. Acute Cardiovasc. Care 8(2), 114–120 (2019). •• Retrospective study comparing vernakalant to flecainide (not compared in any of the available randomized controlled trials).
  MedlineGoogle Scholar
• 49. Simon A, Niederdoeckl J, Janata K et al. Vernakalant and electrical cardioversion for AF - Safe and effective. Int. J. Cardiol. Heart Vasc. 24, 100398–100398 (2019).
  MedlineGoogle Scholar
• 50. Health Canada. Regulatory Decision Summary - Brinavess 190817 (2017). https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00237
  Google Scholar
• 51. O'riordan M. Merck Abandons Oral Vernakalant. Heartwire from Medscape (2012). https://www.medscape.com/viewarticle/760527
  Google Scholar